Cassiano Ricardo Alves Faria Diniz

Cassiano Ricardo Alves Faria Diniz

Auto-generated profile, based on publicly available information

Cassiano Ricardo Alves Faria Diniz

Department of Pharmacology, Ribeirão Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
RMRafael Moliner
Rafael Moliner
MGMykhailo Girych
Mykhailo Girych
CBCecilia A. Brunello
Cecilia A. Brunello
VKVera Kovaleva
Vera Kovaleva
CBCaroline Biojone
Caroline Biojone
ECEero Castren
Eero Castren
Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to TrkB with affinities 1,000-fold higher than those for other antidepressants, and that psychedelics and antidepressants bind to distinct but partially overlapping sites within the transmembrane domain of TrkB dimers. The effects of psychedelics on neurotrophic signaling, plasticity and antidepressant-like behavior in mice depend on TrkB binding and promotion of endogenous BDNF signaling but are independent of serotonin 2A receptor (5-HT2A) activation, whereas LSD-induced head twitching is dependent on 5-HT2A and independent of TrkB binding. Our data confirm TrkB as a common primary target for antidepressants and suggest that high-affinity TrkB positive allosteric modulators lacking 5-HT2A activity may retain the antidepressant potential of psychedelics without hallucinogenic effects.

27 December 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
CDCassiano Ricardo Alves Faria Diniz
Cassiano Ricardo Alves Faria Diniz
ACAna Paula Crestani
Ana Paula Crestani
Since the brain was found to be somehow flexible, plastic, researchers worldwide have been trying to comprehend its fundamentals to better understand the brain itself, make predictions, disentangle the neurobiology of brain diseases, and finally propose up-to-date treatments. Neuroplasticity is simple as a concept, but extremely complex when it comes to its mechanisms. This review aims to bring to light an aspect about neuroplasticity that is often not given enough attention as it should, the fact that the brain’s ability to change would include its ability to disconnect synapses. So, neuronal shrinkage, decrease in spine density or dendritic complexity should be included within the concept of neuroplasticity as part of its mechanisms, not as an impairment of it. To that end, we extensively describe a variety of studies involving topics such as neurodevelopment, aging, stress, memory and homeostatic plasticity to highlight how the weakening and disconnection of synapses organically permeate the brain in so many ways as a good practice of its intrinsic physiology. Therefore, we propose to break down neuroplasticity into two sub-concepts, “upward neuroplasticity” for changes related to synaptic construction and “downward neuroplasticity” for changes related to synaptic deconstruction. With these sub-concepts, neuroplasticity could be better understood from a bigger landscape as a vector in which both directions could be taken for the brain to flexibly adapt to certain demands. Such a paradigm shift would allow a better understanding of the concept of neuroplasticity to avoid any data interpretation bias, once it makes clear that there is no morality with regard to the organic and physiological changes that involve dynamic biological systems as seen in the brain.

1 July 2018 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
CDCassiano R.A.F. Diniz
Cassiano R.A.F. Diniz
PCPlinio Casarotto
Plinio Casarotto
LRLeonardo Resstel
Leonardo Resstel
SJSâmia R.L. Joca
Sâmia R.L. Joca

1 June 2018 in Neuropharmacology
Verified
Journal Article
Open access
CDCassiano R.A.F. Diniz
Cassiano R.A.F. Diniz
PCPlinio Casarotto
Plinio Casarotto
SFSenem M. Fred
Senem M. Fred
CBCaroline Biojone
Caroline Biojone
ECEero Castren
Eero Castren
SJSamia Joca
Samia Joca
The renin-angiotensin system (RAS) is associated with peripheral fluid homeostasis and cardiovascular function, but recent evidence also suggests a functional role in the brain. RAS regulates physiological and behavioral parameters related to the stress response, including depressive symptoms. Apparently, RAS can modulate levels of brain-derived neurotrophic factor (BDNF) and TRKB, which are important in the neurobiology of depression and antidepressant action. However, the interaction between the BDNF/TRKB system and RAS in depression has not been investigated before. Accordingly, in the forced swimming test, we observed an antidepressant-like effect of systemic losartan but not with captopril or enalapril treatment. Moreover, infusion of losartan into the ventral hippocampus (vHC) and prelimbic prefrontal cortex (PL) mimicked the consequences of systemically injected losartan, whereas K252a (a blocker of TRK) infused into these brain areas impaired such effect. PD123319, an antagonist of AT2 receptor (AGTR2), also prevented the systemic losartan effect when infused into PL but not into vHC. Cultured cortical cells of rat embryos revealed that angiotensin II (ANG2), possibly through AGTR2, increased the surface levels of TRKB and its coupling to FYN, a SRC family kinase. Higher Agtr2 levels in cortical cells were reduced after stimulation with glutamate, and only under this condition an interaction between losartan and ANG2 was achieved. TRKB/AGTR2 heterodimers were also observed, in MG87 cells GFP-tagged AGTR2 co-immunoprecipitated with TRKB. Therefore, the antidepressant-like effect of losartan is proposed to occur through a shift of ANG2 towards AGTR2, followed by coupling of TRK/FYN and putative TRKB transactivation. Thus, the blockade of AGTR1 has therapeutic potential as a novel antidepressant therapy.

27 November 2011 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MSMichelle Silva
Michelle Silva
DADaniele C. Aguiar
Daniele C. Aguiar
CDCassiano R. A. Diniz
Cassiano R. A. Diniz
FGFrancisco Silveira Guimarães
Francisco Silveira Guimarães
SJSamia Joca
Samia Joca